Cargando…

Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination

Advances in nucleic acid sequencing technologies have revolutionized the field of genomics, allowing the efficient targeting of mutated neoantigens for personalized cancer vaccination. Due to their absence during negative selection of T cells and their lack of expression in healthy tissue, tumor mut...

Descripción completa

Detalles Bibliográficos
Autores principales: Vormehr, Mathias, Schrörs, Barbara, Boegel, Sebastian, Löwer, Martin, Türeci, Özlem, Sahin, Ugur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710911/
https://www.ncbi.nlm.nih.gov/pubmed/26844233
http://dx.doi.org/10.1155/2015/595363
Descripción
Sumario:Advances in nucleic acid sequencing technologies have revolutionized the field of genomics, allowing the efficient targeting of mutated neoantigens for personalized cancer vaccination. Due to their absence during negative selection of T cells and their lack of expression in healthy tissue, tumor mutations are considered as optimal targets for cancer immunotherapy. Preclinical and early clinical data suggest that synthetic mRNA can serve as potent drug format allowing the cost efficient production of highly efficient vaccines in a timely manner. In this review, we describe a process, which integrates next generation sequencing based cancer mutanome mapping, in silico target selection and prioritization approaches, and mRNA vaccine manufacturing and delivery into a process we refer to as MERIT (mutanome engineered RNA immunotherapy).